P 21 - Shifa Biomedical
Alternative Names: P-21 - Shifa BiomedicalLatest Information Update: 28 Dec 2022
Price :
$50 *
At a glance
- Originator Shifa Biomedical
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action LDL receptor antagonists; PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Dyslipidaemias in USA (PO)
- 19 May 2021 P 21 - Shifa Biomedical is available for licensing as of 19 May 2021. http://shifabiomedical.com/product.html
- 12 May 2021 Shifa Biomedical announces intention to submit IND to US FDA for Dyslipidemia